Citations

Institution: Mayo Clinic Clear

Showing 10 of 108048 citations.

Pathophysiology of Tricuspid Regurgitation
Topilsky, Yan, Tribouilloy, Christophe, Pislaru, Sorin V. , Enriquez‐Sarano, Maurice , Topilsky, Yan , Michelena, Héctor I. , Mahoney, Douglas W. , Sabbah, Michael S. , Enriquez-Sarano, Maurice , Topilsky, Yan

Circulation | September 28, 2010 | Volume: 122 | Issue: 15 | Pages: 1505-1513

10.1161/circulationaha.110.941310 | PMID 20876436 Get It

Background— Respiratory dependence of tricuspid regurgitation (TR), a long-held concept suggested by murmur variation, remains unproven and of unclear mechanisms. Methods and Results— In 41 patients with mild or greater TR (median age, 67 years), we performed triple Doppler echocardiographic quantification (TR severity, right ventricular, and right atrial quantification) with simultaneous respirometer recording of respiratory phases. Expiration to inspiration changes (median) affected TR peak velocity (−40 cm/s; 25th to 75th percentile, −60 to −30 cm/s), duration (−12 milliseconds; 25th to 75th percentile, −45 to 2 milliseconds), and time-velocity integral (−17 cm; 25th to 75th percentile, −23.4 to −10 cm; all P <0.001), consistent with decreased TR driving force. Nevertheless, inspiratory TR augmentation was demonstrated by increased effective regurgitant orifice (0.21 cm 2 ; 25th to 75th percentile, 0.09 to 0.34 cm 2 ) and volume (18 mL per beat; 25th to 75th percentile, 10 to 25 mL per beat; all P <0.001) infrequently detected clinically (2 of 41, 5). As a result of reduced TR driving force, regurgitant volume increased less than effective regurgitant orifice (120 [25th to 75th percentile, 78.6 to 169] versus 169 [ 25th to 75th percentile, 12.9 to 226.1]; P <0.001). During inspiration, right ventricular area increased (diastolic, 27.8 [25th to 75th percentile, 22.6 to 36.3] versus 26.5 [21.1 to 31.9]; P <0.0001) with widening of right ventricular shape (length-to-width ratio, 1.6 [ 25th to 75th percentile, 1.37 to 1.95] versus 1.7 [1.46 to 2.1]; P <0.0001), increased systolic annular diameter ( P =0.003), valve tenting height ( P <0.0001) and area ( P <0.0001), and reduced valvular-to-annular ratio ( P =0.006). Effective regurgitant orifice during inspiration was independently determined by inspiratory valvular-to-annular ratio ( P =0.026) and inspiratory change in right ventricular length-to-width ratio ( P =0.008) and valve tenting area ( P =0.015). Conclusions— TR is dynamic with almost universal respiratory changes of large magnitude and complex pathophysiology. During inspiration, a large increase in effective regurgitant orifice causes, despite a decline in regurgitant gradient, a notable increase in regurgitant volume. Effective regurgitant orifice changes are independently linked to inspiratory annular enlargement (decreased valvular coverage) and to inspiratory right ventricular shape widening with increased valvular tenting. These novel physiological insights into TR respiratory dependence underscore right-side heart plasticity and are important for clinical TR severity evaluation.
Genome-Wide Associations and Functional Genomic Studies of Musculoskeletal Adverse Events in Women Receiving Aromatase Inhibitors
Schaid, Daniel J. , Goss, Paul E., Liu, Mohan , Chapman, Judy-Anne W., Kubo, Michiaki , Jenkins, Gregory D. , Batzler, Anthony , Shepherd, Lois E. , Pater, Joseph L. , Wang, Liewei , Stearns, Vered , Rohrer, Daniel C. , Pritchard, Kathleen I. , Flockhart, David A., Nakamura, Yusuke , Weinshilboum, Richard M. , Ingle, James N. , Mushiroda, Taisei , Chapman, Judy‐Anne W., Ellis, Matthew J. , Goetz, Matthew P. , Weinshilboum, Richard M. , Stearns, Vered

Journal of Clinical Oncology | September 28, 2010 | Volume: 28 | Issue: 31 | Pages: 4674-4682

10.1200/jco.2010.28.5064 | PMID 20876420 Get It

Purpose We performed a case-control genome-wide association study (GWAS) to identify single nucleotide polymorphisms (SNPs) associated with musculoskeletal adverse events (MS-AEs) in women treated with aromatase inhibitors (AIs) for early breast cancer. Patients and Methods A nested case-control design was used to select patients enrolled onto the MA.27 phase III trial comparing anastrozole with exemestane. Cases were matched to two controls and were defined as patients with grade 3 or 4 MS-AEs (according to the National Cancer Institute's Common Terminology Criteria for Adverse Events v3.0) or those who discontinued treatment for any grade of MS-AE within the first 2 years. Genotyping was performed with the Illumina Human610-Quad BeadChip. Results The GWAS included 293 cases and 585 controls. A total of 551,358 SNPs were analyzed, followed by imputation and fine mapping of a region of interest on chromosome 14. Four SNPs on chromosome 14 had the lowest P values (2.23E-06 to 6.67E-07). T-cell leukemia 1A (TCL1A) was the gene closest (926-7000 bp) to the four SNPs. Functional genomic studies revealed that one of these SNPs (rs11849538) created an estrogen response element and that TCL1A expression was estrogen dependent, was associated with the variant SNP genotypes in estradiol-treated lymphoblastoid cells transfected with estrogen receptor alpha and was directly related to interleukin 17 receptor A (IL17RA) expression. Conclusion This GWAS identified SNPs associated with MS-AEs in women treated with AIs and with a gene (TCL1A) which, in turn, was related to a cytokine (IL17). These findings provide a focus for further research to identify patients at risk for MS-AEs and to explore the mechanisms for these adverse events.
Determining the Optimal Approach for Government-Regulated Genetic Testing
Baudhuin, Linnea M.

Clinical Chemistry | September 28, 2010 | Volume: 57 | Issue: 1 | Pages: 7-8

10.1373/clinchem.2010.156687 | PMID 20876227 Get It

Gender, Attention-Deficit/Hyperactivity Disorder, and Reading Disability in a Population-Based Birth Cohort
Yoshimasu, Kouichi , Barbaresi, William J. , Colligan, Robert C., Killian, Jill M. , Voigt, Robert G. , Weaver, Amy L. , Katusic, Slavica K.

Pediatrics | September 28, 2010 | Volume: 126 | Issue: 4 | Pages: e788-e795

10.1542/peds.2010-1187 | PMID 20876182 Get It

OBJECTIVE: To determine the incidence of reading disability (RD) among children with and without research-identified attention-deficit/hyperactivity disorder (ADHD), separately according to gender, in a population-based birth cohort. METHOD: Subjects included all children born in 1976–1982 remaining in Rochester, Minnesota, after 5 years of age (n = 5718). Information from medical, school, and private tutorial records was abstracted. Cumulative incidence of RD, by any of 3 RD formulas, in children with and without ADHD and corresponding hazard ratios (HRs) were calculated separately according to gender. RESULTS: Cumulative incidence of RD by the age of 19 years was significantly higher in children with ADHD (51% in boys, 46.7% in girls) compared with those without ADHD (14.5% in boys, 7.7% in girls). Among children with ADHD, the risk for RD was similar in boys versus girls (HR: 1.0). However, among children without ADHD, boys were 2.0 times more likely than girls to meet RD criteria. Among girls, the HR for the risk for RD associated with ADHD (versus those without ADHD) was 8.1 (95% confidence interval: 5.7–11.5), which was significantly higher than the corresponding HR among boys (3.9 [95% confidence interval: 3.2–4.9]). CONCLUSIONS: The risk for RD is significantly greater among children with ADHD compared with those without ADHD. Among children with ADHD, the risk for RD is the same for boys and girls. However, among children without ADHD, boys are more at risk for RD than girls. Among girls, the magnitude of increased risk for RD associated with ADHD is nearly twice that among boys, because girls without ADHD are less likely to have RD than boys without ADHD.
The Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST)
Mantese, Vito A., Timaran, Carlos H. , Chiu, David, Begg, Richard J., Brott, Thomas G.

Stroke | September 27, 2010 | Volume: 41 | Issue: 10_suppl_1 | Pages: No page available

10.1161/strokeaha.110.595330 | PMID 20876500 Get It

Background and Purpose— Carotid artery stenosis causes up to 10% of all ischemic strokes. Carotid endarterectomy (CEA) was introduced as a treatment to prevent stroke in the early 1950s. Carotid stenting (CAS) was introduced as a treatment to prevent stroke in 1994. Methods— The Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) is a randomized trial with blinded end point adjudication. Symptomatic and asymptomatic patients were randomized to CAS or CEA. The primary end point was the composite of any stroke, myocardial infarction, or death during the periprocedural period and ipsilateral stroke thereafter, up to 4 years. Results— There was no significant difference in the rates of the primary end point between CAS and CEA (7.2% versus 6.8%; hazard ratio, 1.11; 95% CI, 0.81 to 1.51; P =0.51). Symptomatic status and sex did not modify the treatment effect, but an interaction with age and treatment was detected ( P =0.02). Outcomes were slightly better after CAS for patients aged <70 years and better after CEA for patients aged >70 years. The periprocedural end point did not differ for CAS and CEA, but there were differences in the components, CAS versus CEA (stroke 4.1% versus 2.3%, P =0.012; and myocardial infarction 1.1% versus 2.3%, P =0.032). Conclusions— In CREST, CAS and CEA had similar short- and longer-term outcomes. During the periprocedural period, there was higher risk of stroke with CAS and higher risk of myocardial infarction with CEA. Clinical Trial Registration— www.clinicaltrials.gov. Unique identifier: NCT00004732.
EVOLUTION OF A TUMOR-LIKE LESION IN CEREBRORETINAL VASCULOPATHY AND TREX1 MUTATION
Mateen, Farrah J. , Krecke, Karl N. , Younge, BR, Kothari, Parul H., Atkinson, John , Atkinson, John P. , Ford, Andria L. , Shaikh, Abdul Sattar , Mateen, Farrah

Neurology | September 27, 2010 | Volume: 75 | Issue: 13 | Pages: 1211-1213

10.1212/wnl.0b013e3181f4d7ac | PMID 20876473 Get It

Union of forces
Gloviczki, Péter , Gloviczki, Péter

Phlebology: The Journal of Venous Disease | September 24, 2010 | Volume: 25 | Issue: 5 | Pages: 217-218

10.1258/phleb.2010.010e04 | PMID 20870867 Get It

Smoking and Pain
Shi, Yu , Weingarten, Toby N. , Mantilla, Carlos B. , Hooten, W. Michael , Warner, David O. , Mantilla, Carlos B , Weingarten, Toby N

Anesthesiology | September 24, 2010 | Volume: 113 | Issue: 4 | Pages: 977-992

10.1097/aln.0b013e3181ebdaf9 | PMID 20864835 Get It

Cigarette smoke, which serves as a nicotine delivery vehicle in humans, produces profound changes in physiology. Experimental studies suggest that nicotine has analgesic properties. However, epidemiologic evidence shows that smoking is a risk factor for chronic pain. The complex relationship between smoking and pain not only is of scientific interest, but also has clinical relevance in the practice of anesthesiology and pain medicine. This review will examine current knowledge regarding how acute and chronic exposure to nicotine and cigarette smoke affects acute and chronic painful conditions. It will cover the relevant pharmacology of nicotine and other ligands at the nicotinic acetylcholine receptor as related to pain, explore the association of cigarette smoking with chronic painful conditions and potential mechanisms to explain this association, and examine clinical implications for the care of smokers with pain.
Multiplex Detection of IgM and IgG Class Antibodies toToxoplasma gondii, Rubella Virus, and Cytomegalovirus Using a Novel Multiplex Flow Immunoassay
Binnicker, Matthew J. , Jespersen, Deborah J., Harring, Julie

Clinical and Vaccine Immunology | September 23, 2010 | Volume: 17 | Issue: 11 | Pages: 1734-1738

10.1128/cvi.00332-10 | PMID 20861325 Get It

ABSTRACTThe goal of this study was to evaluate the BioPlex 2200Toxoplasma, rubella, and cytomegalovirus (CMV) (ToRC) IgG and IgM multiplex immunoassays (Bio-Rad Laboratories, Hercules, CA) and compare the results to those of conventional testing by enzyme immunoassay (EIA) and enzyme-linked fluorescent assay (ELFA). Serum specimens (n= 600) submitted for routine ToRC IgG and IgM testing by EIA (SeraQuest, Doral, FL; Diamedix, Miami, FL) or ELFA (Vidas; bioMérieux, Durham, NC) were also tested by the BioPlex ToRC multiplex immunoassays. Samples showing discordant results were retested by both methods, with further discrepancies being arbitrated by a third assay. Following repeat testing, the BioPlexToxoplasma, rubella, and CMV IgG assays demonstrated agreements of 98.7 (592/600 specimens), 93.3 (560/600 specimens), and 98.3% (590/600 specimens), respectively, while the ToRC IgM assays yielded agreements of 91.2 (547/600 specimens), 87.3 (524/600 specimens), and 95.2% (571/600 specimens), respectively. The BioPlex ToRC IgG assays provided results comparable to EIA/ELFA results, with kappa coefficients showing near-perfect agreement for theToxoplasma(κ = 0.94) and CMV (κ = 0.97) IgG assays and substantial agreement for the rubella IgG assay (κ = 0.66). The BioPlex ToRC IgM assays showed lower specificity with only slight agreement forToxoplasmaIgM (κ = 0.07), poor agreement for rubella IgM (κ = −0.03), and moderate agreement for CMV IgM (κ = 0.55). Both the BioPlex IgG and IgM assays reduced turnaround time (1.7 h versus 5.5 h by EIA/ELFA for 100 specimens) and eliminated the necessity to manually pipette or aliquot specimens prior to testing.
Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study
Saper, Joel R., Silberstein, Stephen D., McCarville, Sally, Sun, Mark Y., Goadsby, Peter J. , Dodick, David W. , Goadsby, Peter J

Cephalalgia | September 23, 2010 | Volume: 31 | Issue: 3 | Pages: 271-285

10.1177/0333102410381142 | PMID 20861241 Get It

Background: Medically intractable chronic migraine (CM) is a disabling illness characterized by headache ≥15 days per month. Methods: A multicenter, randomized, blinded, controlled feasibility study was conducted to obtain preliminary safety and efficacy data on occipital nerve stimulation (ONS) in CM. Eligible subjects received an occipital nerve block, and responders were randomized to adjustable stimulation (AS), preset stimulation (PS) or medical management (MM) groups. Results: Seventy-five of 110 subjects were assigned to a treatment group; complete diary data were available for 66. A responder was defined as a subject who achieved a 50% or greater reduction in number of headache days per month or a three-point or greater reduction in average overall pain intensity compared with baseline. Three-month responder rates were 39% for AS, 6% for PS and 0% for MM. No unanticipated adverse device events occurred. Lead migration occurred in 12 of 51 (24%) subjects. Conclusion: The results of this feasibility study offer promise and should prompt further controlled studies of ONS in CM.